The diagnostics industry is likely to continue to consolidate, with mid-sized companies particularly vulnerable. But M&A isn't a panacea. Merrill Lynch has graded the progress of top mergers by product integration, cohesive branding, costs savings, and synergies.
You may also be interested in...
Effective medical device regulation supports both safety and innovation needs. This article assesses how well the US FDA and the Australian TGA achieve this balance.
GSK achieved a first-in-class market oncology launch in 2020, but will have to increase that hit rate in order to fulfil its blockbuster ambitions.